ÐÐ°Ð½Ð½Ð°Ñ ÑабоÑа опиÑÑÐ²Ð°ÐµÑ ÑÑавнение двÑÑ Ð¼ÐµÑодов (иммÑноÑеÑменÑного анализа (ÐФÐ) и маÑÑ-ÑпекÑÑомеÑÑии) Ð´Ð»Ñ Ð¾Ð¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ñ ÐºÐ¾Ð½ÑенÑÑаÑии алÑÑа-1-анÑиÑÑипÑина (Ð1ÐТ) в ÑÑвоÑоÑке кÑови Ñеловека. Ð1ÐТ ÑвлÑеÑÑÑ Ð±ÐµÐ»ÐºÐ¾Ð¼ оÑÑÑой ÑÐ°Ð·Ñ (Ñо еÑÑÑ ÐµÐ³Ð¾ конÑенÑÑаÑÐ¸Ñ Ð²Ð¾Ð·ÑаÑÑÐ°ÐµÑ Ð¿Ñи ÑазлиÑнÑÑ Ð²Ð¾ÑпалиÑелÑнÑÑ Ð¿ÑоÑеÑÑÐ°Ñ , коÑоÑÑе пÑоÑекаÑÑ Ð² оÑганизме), поÑÑÐ¾Ð¼Ñ Ð±ÑÑÑÑое и ÑоÑное опÑеделение его конÑенÑÑаÑии позволÑÐµÑ Ð¸ÑполÑзоваÑÑ ÑÑи даннÑе Ð´Ð»Ñ Ð°Ð½Ð°Ð»Ð¸Ð·Ð° пÑоÑÐµÐºÐ°Ð½Ð¸Ñ ÑепÑиÑа Ñ Ð±Ð¾Ð»Ñного, а Ñакже Ð¿Ð¾Ð¼Ð¾Ð³Ð°ÐµÑ Ð² диагноÑÑике ÑазлиÑнÑÑ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸Ð¹ Ð»ÐµÐ³ÐºÐ¸Ñ . Ðа даннÑй Ð¼Ð¾Ð¼ÐµÐ½Ñ ÐºÐ¾Ð½ÑенÑÑаÑÐ¸Ñ Ð1ÐТ Ñеловека опÑеделÑÑÑ Ñ Ð¿Ð¾Ð¼Ð¾ÑÑÑ Ð¸Ð¼Ð¼ÑноÑеÑменÑного анализа, однако ÑÑÐ¾Ñ Ð¼ÐµÑод Ð¸Ð¼ÐµÐµÑ ÑÑд недоÑÑаÑков â наиболее важнÑм из Ð½Ð¸Ñ ÑвлÑеÑÑÑ ÑкоÑоÑÑÑ Ð¿ÑÐ¾Ð²ÐµÐ´ÐµÐ½Ð¸Ñ Ð°Ð½Ð°Ð»Ð¸Ð·Ð° - ÑезÑлÑÑÐ°Ñ Ð¼Ð¾Ð¶Ð½Ð¾ полÑÑиÑÑ ÑолÑко ÑпÑÑÑÑ ÑÑÑки. Так как бÑÑÑÑое и ÑоÑное опÑеделение конÑенÑÑаÑии Ð1ÐТ игÑÐ°ÐµÑ Ð±Ð¾Ð»ÑÑÑÑ ÑÐ¾Ð»Ñ Ð² ÑовÑеменной медиÑине, бÑло пÑедложено иÑполÑзоваÑÑ Ð´Ð»Ñ ÑÑого маÑÑ-ÑпекÑÑомеÑÑиÑеÑкий меÑод, коÑоÑÑй оÑнован на взаимодейÑÑвии ÑÑипÑина Ñ ÐµÐ³Ð¾ оÑновнÑми ингибиÑоÑами â алÑÑа-1-анÑиÑÑипÑином и алÑÑа-2-макÑоглобÑлином, Ð¾Ñ ÐºÐ¾ÑоÑого пÑи взаимодейÑÑвии Ñ ÑÑипÑином оÑÑеплÑеÑÑÑ Ð¿ÐµÐ¿Ñид. ÐаннÑй меÑод бÑл оÑÑабоÑан на ÑÑвоÑоÑÐºÐ°Ñ ÐºÑови конÑÑолÑной гÑÑппÑ, болÑнÑÑ Ñ ÐÐ ÐРи болÑнÑÑ Ð² ÑепÑиÑеÑком ÑоÑÑоÑнии. ÐолÑÑеннÑе знаÑÐµÐ½Ð¸Ñ ÐºÐ¾Ð½ÑенÑÑаÑии Ð1ÐТ бÑли знаÑиÑелÑно вÑÑе Ñ Ð¿Ð°ÑиенÑов Ñ ÑепÑиÑом. РезÑлÑÑаÑÑ, полÑÑеннÑе Ñ Ð¿Ð¾Ð¼Ð¾ÑÑÑ Ð¼ÐµÑода маÑÑ-ÑпекÑÑомеÑÑиÑеÑкого анализа, ÑÑавнивалиÑÑ Ñ ÑезÑлÑÑаÑами поÑле пÑÐ¾Ð²ÐµÐ´ÐµÐ½Ð¸Ñ ÑкÑпеÑименÑа Ñ Ð¿Ð¾Ð¼Ð¾ÑÑÑ ÐФÐ, пÑи ÑÑом Ð´Ð»Ñ Ð¾Ð±ÑазÑов вÑÐµÑ ÑÑÐµÑ Ð³ÑÑпп не бÑло найдено ÑÑÑеÑÑвеннÑÑ Ð¾ÑлиÑий, ÑÑо позволÑÐµÑ ÑделаÑÑ Ð²Ñвод о Ñом, ÑÑо маÑÑ-ÑпекÑÑомеÑÑиÑеÑкий меÑод позволÑÐµÑ ÑоÑно опÑеделÑÑÑ ÐºÐ¾Ð½ÑенÑÑаÑÐ¸Ñ Ð°Ð»ÑÑа-1-анÑиÑÑипÑина в ÑÑвоÑоÑке кÑови Ñеловека., This work describes a comparison of two methods (enzyme immunoassay (ELISA) and mass spectrometry) for determining the concentration of alpha-1-antitrypsin (A1AT) in human serum. A1AT is an acute phase protein (that is, its concentration increases with various inflammatory processes that occur in the body), so a quick and accurate determination of its concentration allows you to use this data to analyze the course of sepsis in a patient, and also helps in the diagnosis of various lung diseases. At the moment, the concentration of human A1AT is determined using an enzyme immunoassay, but this method has a number of disadvantages â the result can be obtained only after a day. Since the rapid and accurate determination of the concentration of A1AT plays an important role in modern medicine, it was proposed to use a mass spectrometric method for this purpose, which is based on the interaction of trypsin with its main inhibitors â alpha-1-antitrypsin and alpha-2-macroglobulin, from which the peptide is cleaved off when interacting with trypsin. This method was tested on the blood sera of the control group, patients with ARVI and patients in a septic state. The obtained values of A1AT concentration were significantly higher in patients with sepsis. The results obtained by mass spectrometric analysis were compared with the results obtained after the experiment with ELISA, while no significant differences were found for the samples of all three groups, which allows us to conclude that the mass spectrometric method allows us to accurately determine the concentration of alpha-1-antitrypsin in human serum.